Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has ...

indicating significant advancements in their drug discovery capabilities. The company’s proprietary AI-driven platform, PEDAL, demonstrates a high accuracy rate of 92% in predicting tumor ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...

Artificial intelligence and robotics are revolutionizing drug discovery by automating laboratory processes and enabling rapid ...

Dr. D. Wade Clapp's work with British biotech company Healx dates to 2019. Photo by Liz Kaye, Indiana University Indiana ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor ...

Startup Persist AI, which launched a cloud lab to accelerate pharmaceutical formulation development, raised $12 million in a ...